# Quoin Pharmaceuticals Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Quoin Pharmaceuticals Ltd.). ## Overview Quoin Pharmaceuticals Ltd. is a United States-based late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases. The company is developing proprietary therapeutic drug products, with QRX003 as its lead program and additional work on QRX009 and topical rapamycin formulations. ## Products & services • QRX003 topical lotion for Netherton Syndrome • QRX009 clinical-stage rare disease program • Topical rapamycin (sirolimus) formulation research • Rare-disease drug development and clinical testing • Regulatory and commercialization preparation for orphan drugs - **Lead drug candidate development** (55%) — Clinical development of QRX003 for Netherton Syndrome and related rare skin diseases. - **Pipeline expansion programs** (20%) — Development work on QRX009 and other rare-disease candidates. - **Formulation research** (15%) — Research into topical rapamycin-based formulations for orphan indications. - **Regulatory and access preparation** (10%) — Activities supporting approvals, orphan designations, and launch readiness. - QRX003 topical lotion for Netherton Syndrome - QRX009 clinical-stage rare disease program - Topical rapamycin (sirolimus) formulation research - Rare-disease drug development and clinical testing - Regulatory and commercialization preparation for orphan drugs ## Customers Quoin does not yet sell commercial products, so its near-term counterparties are primarily regulators, clinical investigators, trial participants, and development partners rather than end-market buyers. If approved, the company expects its therapies to be used by patients with rare genetic skin diseases, with commercialization supported through its own sales infrastructure in some markets and distribution partners in others. The value proposition is concentrated in diseases with limited or no approved treatments, where clinical benefit and regulatory designation can shape adoption. - **Rare disease patients** (primary) — Patients with Netherton Syndrome and related genetic skin disorders who would use QRX003 or similar therapies if approved. - **Clinical trial network** (primary) — Hospitals, investigators, and study coordinators that enroll and monitor patients in late-stage trials. - **Regulatory agencies** (primary) — FDA, European, Japanese, and Saudi regulators that determine designations, trial requirements, and approval pathways. - **Commercial partners** (secondary) — Regional distribution and licensing partners that may help launch products outside Quoin's direct-sales markets. - Patients with Netherton Syndrome and related rare skin diseases - Clinical trial sites and investigators running QRX003 studies - Regulators such as FDA, MHLW, Saudi FDA, and EU agencies - Distribution partners in non-core launch markets - Future prescribing specialists treating orphan dermatology patients ## Geography Quoin is headquartered in the United States and is building a multi-region regulatory and commercialization path for QRX003. Its planned launch footprint includes the U.S., Europe, and Japan directly, with partner-led distribution in Canada, Australia/New Zealand, the Middle East, China, Hong Kong, Taiwan, Latin America, Central and Eastern Europe, Turkey, and Singapore. Geography matters because rare-disease approvals, reimbursement, and partner structures differ materially across these markets. - United States is the core operating base and lead approval market - Europe and Japan are priority direct-commercialization regions - Canada, Australia/NZ, and Asia are planned partner markets - Middle East and Saudi Arabia are relevant for expedited pathways - Cross-border execution depends on separate regulatory approvals ## Strategy Quoin's strategy is centered on advancing QRX003 through late-stage clinical testing, securing regulatory designations, and preparing for commercialization in rare-disease markets. It is also expanding the pipeline through QRX009, topical rapamycin research, and external business development, while maintaining flexibility to partner, license, or pursue other transactions. - **Complete late-stage QRX003 development** (short-term) — Regulatory approval is the main value-creation event for the lead asset and the basis for future revenue. - **Prepare commercialization infrastructure** (medium-term) — Rare-disease launches require specialized medical education, distribution, and market-access capabilities. - **Broaden the pipeline** (medium-term) — A second and third program can reduce single-asset dependency and extend long-term growth options. - **Use external collaborations to expand reach** (long-term) — Partnerships can speed geographic expansion and conserve internal resources in a capital-intensive model. - Advance QRX003 through Phase 3 and potential filings - Use orphan, fast-track, and breakthrough designations to de-risk approval - Build direct sales capability in the U.S., Europe, and Japan - Use distribution partners for additional international markets - Expand the pipeline with QRX009 and topical rapamycin - Pursue licensing and partnership opportunities to broaden reach ## Risks Quoin is exposed to the core risks of late-stage drug development: trial failure, delays, additional regulatory requirements, and uncertainty around approval pathways. As a pre-revenue biotechnology company, it also depends on external financing and may face dilution, restricted access to capital, and commercialization execution risk if any product is approved. Its single-lead-asset profile adds concentration risk until the pipeline broadens. - **Clinical development failure or delay** [critical] — QRX003 and other candidates are still in late-stage testing and may not achieve the required efficacy, safety, or timelines. - **Regulatory uncertainty** [high] — FDA and foreign agencies could require additional trials, different designs, or more evidence before approval. - **Financing and dilution risk** [critical] — The business is pre-revenue and depends on external capital to fund R&D and commercialization. - **Nasdaq listing risk** [high] — Failure to meet continued listing requirements could threaten market access and investor confidence. - **Commercialization execution risk** [medium] — Even with approval, Quoin must build sales, market access, and distribution capabilities for rare-disease launches. - Clinical trial outcomes may not support approval - Regulatory agencies may require additional studies - Funding needs could force dilution or delay programs - Nasdaq listing compliance remains a risk - Commercial launch execution is unproven - Pipeline concentration increases dependence on QRX003 ## Accounting Quoin's reported results are dominated by R&D expense timing, clinical program spend, and equity-based compensation rather than product revenue. Because the company is pre-commercial, investors should focus on capital raise terms, share dilution, and the accounting for acquired or licensed intangible assets, which can affect operating expense allocation and future impairment risk. Interest income and marketable securities activity also matter because they offset part of the cash burn while the company remains in development mode. - **Research and development expense recognition** — Affects operating loss and comparability across periods - **Stock-based compensation** — Increases reported R&D and G&A expense - **Intangible asset amortization** — Affects R&D expense and carrying value of IP - **Liquidity and going-concern assessment** — Influences capital markets perception and solvency analysis - R&D expense timing reflects clinical trial and development milestones - Stock-based compensation affects reported operating losses - Intangible asset amortization is included in R&D expense - Marketable securities and interest income offset cash usage - Future commercialization could trigger revenue recognition judgment - Asset impairment risk exists for capitalized intangibles --- *Last updated: 2026-09-28T10:45:36.955826+00:00*